Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Equity-to-Asset Related Terms
Guangzhou Baiyunshan Pharmaceutical Holdings Co Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Equity-to-Asset Chart
Guangzhou Baiyunshan Pharmaceutical Holdings Co Annual Data
FRA:GU5 vs MCK, COR, CAH: Equity-to-Asset Comparison
For the Medical Distribution subindustry, Guangzhou Baiyunshan Pharmaceutical Holdings Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Equity-to-Asset vs Medical Distribution Industry
Guangzhou Baiyunshan Pharmaceutical Holdings Co Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) has a Equity-to-Asset of 0.47 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors. This is near median its historical median of 0.45. Over the past decade, Guangzhou Baiyunshan Pharmaceutical Holdings Co's Equity-to-Asset has ranged from 0.42 to 0.69. According to the industry distribution chart, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks #53 out of 124 companies in the Medical Distribution industry, placing it in the top 42.7%.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co's Equity-to-Asset too high?
Guangzhou Baiyunshan Pharmaceutical Holdings Co's current Equity-to-Asset of 0.47 is near median its 10-year median of 0.45. Over the past 10 years, this metric has ranged from a low of 0.42 to a high of 0.69. The Medical Distribution industry median Equity-to-Asset is 0.40. Guangzhou Baiyunshan Pharmaceutical Holdings Co's value of 0.47 is 19% above this industry median. Based on the distribution chart, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks #53 out of 124 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Guangzhou Baiyunshan Pharmaceutical Holdings Co has a GF Score™ of 65/100, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Baiyunshan Pharmaceutical Holdings Co's Equity-to-Asset compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks #53 out of 124 companies for Equity-to-Asset. This puts Guangzhou Baiyunshan Pharmaceutical Holdings Co in the upper half of its industry. The industry median Equity-to-Asset is 0.40. Guangzhou Baiyunshan Pharmaceutical Holdings Co's value of 0.47 is 19% above this benchmark. Historically, Guangzhou Baiyunshan Pharmaceutical Holdings Co's own Equity-to-Asset has ranged from 0.42 to 0.69 over the past decade. While the company's 10-year median is 0.45 vs. the industry median of 0.40, Guangzhou Baiyunshan Pharmaceutical Holdings Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Distribution company?
The median Equity-to-Asset among Medical Distribution companies is 0.40, based on 124 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guangzhou Baiyunshan Pharmaceutical Holdings Co's current Equity-to-Asset of 0.47 is 19% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors. For the Medical Distribution industry, the median Equity-to-Asset is 0.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guangzhou Baiyunshan Pharmaceutical Holdings Co's current Equity-to-Asset is 0.47, which is near median its own 10-year median of 0.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co stock overvalued right now?
Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) has a current Equity-to-Asset of 0.47. The stock's GF Value™ is €2.04, compared to a current price of €1.44 — trading 29.4% below its estimated fair value. The current Equity-to-Asset is 0.47, which is near median its 10-year median of 0.45 and 19% above the Medical Distribution industry median of 0.40. Guangzhou Baiyunshan Pharmaceutical Holdings Co's overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5), the current Equity-to-Asset is 0.47 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) Overvalued in 2026?
Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co stock appears to be undervalued.
The current stock price of €1.44 is trading 29.4% below its estimated GF Value™ of €2.04.
Key valuation signals for FRA:GU5:
Equity-to-Asset: 0.47 (near median its 10-year median of 0.45)
GF Value™: €2.04 vs. price of €1.44 (29.4% below fair value)
Industry Position: 19% above the Medical Distribution median (#53 of 124)
No single metric tells the full story. See the FRA:GU5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is engaged in the pharmaceutical and healthcare industry, focusing on the development of a full industrial chain covering research, manufacturing, and distribution. The group operates through five reportable segments. The Modern Chinese Medicine segment involves the R&D, manufacturing, and sale of proprietary Chinese and natural medicines. The Chemical Pharmaceutical Technology segment focuses on chemical drugs, APIs, and intermediates. The Natural Beverages segment produces and sells health-oriented beverage products. The Pharmaceutical Commerce segment is engaged in the wholesale, retail, and import/export of medicines and medical devices. The Other Segments include biotechnology innovation, consumer health, and medical services.
65GF Score
Get the complete analysis for FRA:GU5
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GU5 has been successfully added to your 
